Work Here?
Overview
Immunome identifies antibodies and their targets by studying the immune systems of patients who recover from diseases, to develop first-in-class therapeutics. Its platform analyzes immune responses to discover novel antibodies and their targets, which are then advanced through research and development in partnership with healthcare and medical research clients. The company’s products work by using antibodies discovered from patients’ immune systems to target diseases, potentially enabling new treatments across oncology and other areas. Immunome differentiates itself through a proprietary discovery platform that extracts clinically relevant antibodies from real patient immune responses, enabling collaborations and licensing deals rather than solely pursuing standalone drug sales. The goal is to bring new antibody therapies to patients by forming partnerships, licensing innovations, and eventually delivering approved therapies.
About Immunome
Industries
Biotechnology
Healthcare
Company Size
201-500
Company Stage
IPO
Headquarters
Bothell, Washington
Founded
2008
Your Connections
People at Immunome who can refer or advise you
Simplify's Take
What believers are saying
- NDA filing for varegacestat creates near-term commercial revenue to fund ADC pipeline.
- IND clearance and first dosing of IM-1617 in June 2026 validate undisclosed-target strategy.
- Broad early-stage ADC portfolio against solid tumors supports multiple partnering opportunities.
What critics are saying
- FDA rejection of varegacestat NDA within 6–12 months eliminates critical cash bridge funding.
- Undisclosed RTK target validation failure in IM-1617 first-in-human trial kills the program.
- Daiichi Sankyo and AstraZeneca dominate TOP1 ADC space, compressing Immunome's partnering leverage.
What makes Immunome unique
- IM-1617 targets an undisclosed RTK driving both tumor survival and immune exclusion.
- HC74 payload is a proprietary topoisomerase I inhibitor distinct from dominant DXd platforms.
- Varegacestat offers an NDA-filed gamma secretase inhibitor with 84% progression risk reduction.
Help us improve and share your feedback! Did you find this helpful?
Funding
Total Funding
$1B
Above
Industry Average
Funded Over
13 Rounds
Benefits
Health Insurance
Dental Insurance
Vision Insurance
401(k) Retirement Plan
401(k) Company Match
Unlimited Paid Time Off
Hybrid Work Options
Flexible Work Hours
Remote Work Options
Paid Vacation
Paid Holidays
Wellness Program
Mental Health Support
Conference Attendance Budget
Professional Development Budget
Stock Options
Company Equity
Phone/Internet Stipend
Home Office Stipend
Stock Price
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↑ 0%2 year growth
↓ -10%Immunome's Chief Scientific Officer Jack Higgins sold 9,438 shares on 2 April for $204,238, reducing his direct holdings by 30% to 22,000 shares. The sale was executed under a pre-arranged Rule 10b5-1 trading plan established in December 2025 for financial diversification. The transaction comes as the clinical-stage biotechnology company approaches a significant milestone: its lead candidate varegacestat met the primary endpoint in a Phase 3 trial in December 2025, with an FDA submission planned for the second quarter of 2026. Immunome expects three additional investigational new drug applications and early data from IM-1021 across 2026. The company's stock has risen 250% over the past year, bringing its market capitalisation to $2.40 billion.
Immunome has reported a reduced full-year net loss of $212.39 million for 2025 and filed a $156.03 million common stock shelf registration linked to an employee stock option plan offering. The biotechnology company also updated investors on progress in its oncology pipeline. The company plans to file a New Drug Application for varegacestat following positive Phase 3 data, with multiple solid tumour investigational new drug applications also in development. However, Immunome remains deeply unprofitable despite the narrower losses. The shelf registration raises concerns about potential equity dilution and ownership overhang. Fair value estimates from analysts vary widely, ranging from approximately $29 to over $215 per share, reflecting significant uncertainty around the company's prospects as it advances its high-risk oncology platform.
Immunome to present at 44th Annual J.P. Morgan Healthcare Conference. Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Immunome management will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026 at 10:30 a.m. PST. Interested parties can access a live audio webcast of the presentation via the Investor Relations section of Immunome's website at www.immunome.com. A replay webcast will be available for approximately 30 days following the live presentation. Immunome is a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class targeted cancer therapies. We are advancing an innovative portfolio of therapeutics, drawing on leadership that previously played key roles in the design, development, and commercialization of cutting-edge therapies, including antibody-drug conjugate therapies. Our pipeline includes varegacestat, a late-clinical stage GSI; IM-1021, a clinical-stage ROR1 ADC; and IM-3050, a FAP-targeted radiotherapy that recently received IND clearance. We are also advancing a broad portfolio of early-stage ADCs pursuing undisclosed solid tumor targets. For more information, visit www.immunome.com. View source version on businesswire.com: https://www.businesswire.com/news/home/20260106254447/en/
Immunome, Inc. (“Immunome”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today a...
Immunome, Inc. (“Immunome”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies,
Immunome is Hiring for 17 Jobs on Simplify!
Find jobs on Simplify and start your career today
About Immunome
Industries
Biotechnology
Healthcare
Company Size
201-500
Company Stage
IPO
Headquarters
Bothell, Washington
Founded
2008
Immunome is Hiring for 17 Jobs on Simplify!
Find jobs on Simplify and start your career today